Compare PVH & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVH | WGS |
|---|---|---|
| Founded | 1881 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Apparel | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 1994 | N/A |
| Metric | PVH | WGS |
|---|---|---|
| Price | $66.43 | $57.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 7 |
| Target Price | $89.27 | ★ $140.71 |
| AVG Volume (30 Days) | ★ 808.9K | 679.7K |
| Earning Date | 03-31-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.72 | N/A |
| Revenue | ★ $8,652,900,000.00 | N/A |
| Revenue This Year | $3.66 | $29.98 |
| Revenue Next Year | $1.79 | $26.04 |
| P/E Ratio | ★ $17.88 | $1,251.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $59.28 | $55.17 |
| 52 Week High | $89.79 | $170.87 |
| Indicator | PVH | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 27.96 |
| Support Level | $60.58 | N/A |
| Resistance Level | $71.32 | $95.75 |
| Average True Range (ATR) | 2.08 | 4.43 |
| MACD | 0.49 | -1.25 |
| Stochastic Oscillator | 71.50 | 5.64 |
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, about 1,400 stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.